A multicenter study finds no difference in outcomes between frail and nonfrail elderly patients treated with tildrakizumab ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a study titled ‘Prospective ...

Health experts reveal the impact of the inflammatory skin condition on joints, and highlight symptoms and management tips ...

Psoriasis is a long-term disease that affects the immune system. It makes skin cells grow too fast. Instead of new cells ...

Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...

Psoriasis is a chronic skin disorder causing red, scaly plaques, affecting various body parts, with varying severity levels.

APREMILAST demonstrated sustained efficacy and a consistent safety profile over 52 weeks in paediatric patients with moderate ...

Large cohort study finds TNF inhibitors linked to lower cancer risk in psoriasis, supporting long-term safety of biologic ...

Patients with severe psoriasis who were treated with TNFi long-term had a lower risk of developing PsA than those treated with phototherapy.

Switching to a different class of biologic improves psoriasis outcomes but may raise infection risk in some cases, a ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for ...